|By PR Newswire||
|March 7, 2014 02:00 PM EST||
PHOENIX, March 7, 2014 /PRNewswire-USNewswire/ -- Not only are neuropathic pain symptoms quite common in knee osteoarthritis (OA), but scientists can predict who will respond to treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) by assessing the nervous system's own capacity to regulate pain, new research suggests. Patients whose tests had indicated superior conditioned pain modulation (CPM) had less pain and fewer neuropathic symptoms at study's end, in results reported in a scientific poster today at the 30th Annual Meeting of the American Academy of Pain Medicine.
"Clinically, these results indicate that neuropathic symptoms are very common in knee OA and that neuropathic processes -- such as changes in conditioned modulation -- predict who will respond to a common treatment for knee OA," said Ajay D. Wasan, MD, MSc, the principal investigator, vice chair for Pain Medicine at UPMC, and a visiting professor at the University of Pittsburgh in Pennsylvania.
Furthermore, Dr. Wasan said, "Patients with neuropathic pain symptoms in OA respond equally as well to topical NSAIDs as those who do not have neuropathic pain symptoms."
Investigators conducted a 5-week effectiveness study of diclofenac topical gel, an NSAID, in 44 patients with knee OA (i.e., arthritis caused by a breakdown of the lining of the joints). Patients were extensively tested as to genetically and environmentally influenced physical characteristics. Methods included the use of the Neuropathic Pain Questionnaire (NPQ), the Knee Injury and Osteoarthritis Outcome Score (KOOS, a multidimensional pain and functional assessment), an exercise performance task and quantitative sensory testing (QST).
QST uses brief computer-applied painful stimuli as well as sophisticated manually-applied pain sensitivity testing (such as heat, cold, pressure and pinprick) to assess how the nervous system responds to painful stimuli. QST has been used to identify a range of sensory abnormalities in patients with neuropathic pain (Maier et al, Pain 2010;150(3):439-50).
Institutional Review Board approval and written consent were obtained for the study, which was funded by an investigator-initiated grant from Endo Pharmaceuticals (Nasdaq: ENDP).
Of 38 subjects who completed the study, 40% had significant neuropathic symptoms, with a mean of 35/100 on a pain scale, that included burning or shooting sensations and sensitivity to touch. Pain sensitivity at baseline, as measured by QST, had modest correlation to symptoms (.4-.50, p < .01).
After 4 weeks of treatment with diclofenac gel, there
SOURCE American Academy of Pain Medicine
Aug. 24, 2016 01:00 AM EDT Reads: 1,567
Aug. 24, 2016 12:45 AM EDT Reads: 2,014
Aug. 24, 2016 12:30 AM EDT Reads: 1,816
Aug. 24, 2016 12:00 AM EDT Reads: 2,769
Aug. 23, 2016 11:30 PM EDT Reads: 2,203
Aug. 23, 2016 11:00 PM EDT Reads: 3,477
Aug. 23, 2016 09:15 PM EDT Reads: 1,637
Aug. 23, 2016 09:00 PM EDT Reads: 2,960
Aug. 23, 2016 08:45 PM EDT Reads: 3,735
Aug. 23, 2016 08:15 PM EDT Reads: 1,384
Aug. 23, 2016 08:15 PM EDT Reads: 1,622
Aug. 23, 2016 07:45 PM EDT Reads: 1,224
Aug. 23, 2016 07:00 PM EDT Reads: 3,787
Aug. 23, 2016 06:30 PM EDT Reads: 281
Aug. 23, 2016 05:00 PM EDT Reads: 2,882